Ion Beam Applications

Ion Beam Applications, commonly known as IBA, is a Belgian medical-technology company headquartered in Louvain-la-Neuve. Founded in 1986 by physicist and engineer Yves Jongen within the Cyclotron Research Center of the University of Louvain, the company began as a university spin-off focused on applying accelerator and ion-beam science to practical medical and industrial uses. Its activities have since developed around four closely related areas: proton therapy, radiopharmacy, dosimetry, and industrial sterilisation. IBA is particularly associated with proton therapy, a form of radiation treatment that uses protons rather than conventional X-rays to target tumours. The company develops and supplies accelerator-based systems, treatment-room equipment, and integrated proton-therapy-centre solutions. These systems are part of the infrastructure used by specialist cancer-treatment centres, and the company's work connects accelerator engineering, radiation physics, treatment delivery, and clinical operations. IBA installed its first proton-therapy equipment at Massachusetts General Hospital in Boston in 2001. It later supplied equipment for the University of Pennsylvania's Proton Center, which opened in 2009. These projects helped establish the company as an international supplier in a technically demanding segment of oncology equipment. Beyond treatment systems, IBA operates in radiopharmacy, where cyclotrons and related technologies are used to produce radioisotopes and radiopharmaceuticals for diagnostic imaging and medical treatment. Its dosimetry activities address the measurement and control of radiation dose, an important requirement in radiotherapy, imaging, and radiation-protection applications. The company also applies ionising-radiation technology to industrial sterilisation, extending its expertise beyond healthcare delivery. IBA's business is international in scope. Reference material describes a workforce of approximately 1,500 people operating across about 40 locations, although the exact employee count and site footprint can change over time. The company has supplied equipment and services to Proton Partners International for a planned network of proton-beam-therapy centres in the United Kingdom. In 2017, IBA announced a €16 million investment in a new logistics and production centre in Louvain-la-Neuve, reinforcing its Belgian base and supporting manufacturing and distribution activities. IBA's positioning is that of a specialised, high-technology supplier rather than a consumer-facing healthcare brand. Its value proposition rests on accelerator expertise, integrated treatment infrastructure, radiation measurement, and the supporting technologies needed to produce and use medical isotopes. The company operates at the intersection of medical devices, oncology infrastructure, nuclear medicine, and industrial radiation processing. Its history reflects the commercialisation of university-based accelerator research into a global portfolio serving hospitals, radiopharmacies, research and medical institutions, and industrial customers.

Ion Beam Applications was established in 1986 by Yves Jongen within the Cyclotron Research Center of the University of Louvain, now associated with UCLouvain. Its creation followed the university-spinoff model: research and engineering capabilities developed in an academic accelerator environment were organised into a commercial company addressing medical and industrial applications of ion beams. From the beginning, the company's technical identity was tied to cyclotrons, particle accelerators, and the controlled production and use of radiation. The company's early development led toward proton therapy, a specialised cancer-treatment technology that uses accelerated protons to deliver radiation to tumours. Proton therapy requires more than an accelerator alone; it also involves beam transport, treatment rooms, patient positioning, dose control, and integration with clinical workflows. IBA developed equipment and integrated proton-therapy-centre solutions, creating a business model based on supplying complex systems to hospitals and specialist treatment providers. A major early reference project came in 2001, when IBA installed its first proton-therapy equipment for Massachusetts General Hospital in Boston. This installation was an important step in the commercialisation of the company's technology and in its emergence as an international supplier to leading medical institutions. In 2009, IBA supplied equipment for the University of Pennsylvania's Proton Center, adding another prominent institutional installation to its proton-therapy record. IBA's activities expanded beyond proton-therapy treatment systems. The company became active in radiopharmacy solutions, using cyclotron and accelerator technologies to support the production and handling of radioisotopes and radiopharmaceuticals. These materials are used in nuclear medicine, including diagnostic imaging and therapeutic applications. IBA also developed a dosimetry business concerned with measuring radiation dose and supporting quality and safety requirements in medical and radiation-related environments. A further activity is industrial sterilisation, in which ionising radiation is used to treat products and materials. The company continued to build an international presence through projects, equipment supply, and services. Reference material describes approximately 1,500 employees distributed across around 40 locations, indicating a substantial global operating footprint rather than a business limited to its Belgian origins. IBA also supplied equipment and services to Proton Partners International, which was developing three proton-beam-therapy centres in the United Kingdom. In 2017, IBA invested €16 million in a new logistics and production centre in Louvain-la-Neuve. The investment strengthened the company's home base and reflected the operational requirements of a business that designs, produces, delivers, and supports sophisticated accelerator and medical systems. Across its history, IBA has therefore combined a university-derived technology platform with international project execution. Its principal identity remains that of a specialist supplier to proton therapy and nuclear medicine, while its dosimetry and industrial-sterilisation activities extend the use of its radiation expertise into adjacent markets.

• 2017

  Louvain-la-Neuve production and logistics investment

  [1]Ion Beam Applicationsen.wikipedia.org

  IBA invested €16 million in a new logistics and production centre in Louvain-la-Neuve.

• 2009

  University of Pennsylvania Proton Center project

  [1]Ion Beam Applicationsen.wikipedia.org

  IBA supplied equipment for the University of Pennsylvania's Proton Center.

• 2001

  First proton-therapy equipment installed

  [1]Ion Beam Applicationsen.wikipedia.org

  IBA installed its first proton-therapy equipment for Massachusetts General Hospital in Boston.

• 1986

  IBA founded as a university spin-off

  [1]Ion Beam Applicationsen.wikipedia.org

  Yves Jongen founded Ion Beam Applications within the Cyclotron Research Center of the University of Louvain, creating a commercial company based on accelerator and ion-beam research.

Specialised medical-technology and accelerator-science company serving oncology, nuclear medicine, radiation measurement, and industrial sterilisation markets.

• Radiotherapy equipment

  Proton-therapy systems

  IBA develops accelerator-based proton-therapy equipment and integrated proton-therapy-centre solutions for cancer treatment. The offering involves the systems required to generate, transport, control, and deliver therapeutic proton beams in specialist clinical environments. Its reference installations include equipment supplied to Massachusetts General Hospital and the University of Pennsylvania's Proton Center.

• Particle accelerators

  Cyclotrons and accelerator systems

  Cyclotrons and related accelerator technologies form the technical foundation of IBA's medical and industrial businesses. They are used in applications including proton therapy and the production of radioisotopes for radiopharmacy. The company's origins in the University of Louvain's Cyclotron Research Center are central to this product area.

• Nuclear medicine

  Radiopharmacy solutions

  IBA provides radiopharmacy solutions associated with the production and use of medical radioisotopes and radiopharmaceuticals. These technologies support nuclear-medicine applications, including diagnostic and therapeutic workflows, and extend the company's accelerator expertise beyond external-beam radiotherapy.

• Radiation measurement

  Dosimetry solutions

  IBA's dosimetry activities focus on the measurement and control of radiation dose. Such capabilities support radiotherapy quality assurance, radiation safety, and other applications where accurate dose assessment is required. The business complements the company's treatment-system and accelerator activities.

• Industrial radiation processing

  Industrial sterilisation systems

  IBA applies ionising-radiation technology to industrial sterilisation. This activity uses the company's expertise in controlled radiation generation and delivery for non-clinical processing applications, broadening its portfolio beyond hospitals and nuclear-medicine facilities.

• 2017

  Investment in a new Louvain-la-Neuve logistics and production centreStrategy

  Background

  IBA required additional logistics and production capacity to support its international medical-technology and accelerator businesses.

  Action taken

  The company invested €16 million in constructing a new logistics and production centre in Louvain-la-Neuve.

  Aftermath

  The investment reinforced IBA's Belgian operational base. The supplied reference material does not provide further quantified outcomes.

  Investment amount. €16 million committed (2017)

  Source

1. 1Ion Beam Applicationsen.wikipedia.org
2. 2Ion Beam Applications official websiteiba-worldwide.com